KOMIPHARM INTERNATIONAL (041960) Financial Statements

OverviewFinancialsChecksFilings

In fiscal year 2025, KOMIPHARM INTERNATIONAL (041960) reported revenue of 52.5 billion KRW.

Income Statement

YearRevenueOp ProfitNet IncomeSource
202552.5 billion KRW2.0 billion KRW-8.0 billion KRW[source]
202458.8 billion KRW6.2 billion KRW14.7 billion KRW[source]
202342.6 billion KRW-6.3 billion KRW-5.9 billion KRW[source]
202239.8 billion KRW-3.8 billion KRW-7.5 billion KRW[source]
202135.8 billion KRW-5.3 billion KRW-5.9 billion KRW[source]

Balance Sheet

YearTotal AssetsTotal LiabilitiesTotal EquitySource
2025148.3 billion KRW61.2 billion KRW87.1 billion KRW[source]
2024132.4 billion KRW55.8 billion KRW76.6 billion KRW[source]
2023127.2 billion KRW55.8 billion KRW71.3 billion KRW[source]
2022116.5 billion KRW46.0 billion KRW70.4 billion KRW[source]
2021116.2 billion KRW42.4 billion KRW73.8 billion KRW[source]

Cash Flow

YearOperatingInvestingFinancingSource
2025-622 million KRW5.8 billion KRW10.2 billion KRW[source]
20248.8 billion KRW2.0 billion KRW-13.2 billion KRW[source]
2023-2.8 billion KRW-3.5 billion KRW10.5 billion KRW[source]
2022-1.8 billion KRW-1.4 billion KRW2.0 billion KRW[source]
2021-1.3 billion KRW-745 million KRW-1.0 billion KRW[source]
Financials & Filings: DART (traceable by receipt number) · Prices: Financial Services Commission · Data Sources · Last checked: 2026-08-29 · About · Delisting market cap threshold: KOSPI 5B KRW / KOSDAQ 4B KRW (per listing rules) · This page provides factual information, not investment advice